Long-Term Administration of Endothelin Receptor Antagonist Improves Coronary Endothelial Function in Patients With Early Atherosclerosis | Zendy

Martin Reriani | Zendy; Eugenia Raichlin | Zendy; Abhiram Prasad | Zendy; Verghese Mathew | Zendy; Geralyn M. Pumper | Zendy; Rebecca E. Nelson | Zendy; Ryan J. Len | Zendy; Charanjit S. Rihal | Zendy; Lilach O. Lerman | Zendy; Amir Lerman | Zendy

Open Access

Long-Term Administration of Endothelin Receptor Antagonist Improves Coronary Endothelial Function in Patients With Early Atherosclerosis

Author(s) -

Martin Reriani,

Eugenia Raichlin,

Abhiram Prasad,

Verghese Mathew,

Geralyn M. Pumper,

Rebecca E. Nelson,

Ryan J. Len,

Charanjit S. Rihal,

Lilach O. Lerman,

Amir Lerman

Publication year - 2010

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.110.967406

Subject(s) - medicine , endothelin receptor , endothelin receptor antagonist , cardiology , antagonist , receptor antagonist , term (time) , receptor , physics , quantum mechanics

Endothelin (ET-1) is one of the most potent vasoconstrictors and plays a seminal role in the pathogenesis of atherosclerosis. The present study was designed to test the hypothesis that long-term treatment with an endothelin-A (ET(A)) receptor antagonist improves coronary endothelial function in patients with early coronary atherosclerosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research